Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | AML: Vaccination, hypomethylation and CAR-T

David Avigan • 13 Sep 2019
IMW 2019
Acute Myeloid Leukemia

David Avigan, MD, Harvard Medical School, Boston, MA, discusses the efficacy of using hypomethylating agents to increase the potency of dendritic cell hybridoma acute myeloid leukemia (AML) vaccines. Dr Avigan also discusses how the combination of the aforementioned vaccine with CAR T-cell therapy may offer a potentially powerful therapy for patients. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from David Avigan

2:26
Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
David Avigan • 26 Aug 2022
1:26
The role of vaccines in AML
David Avigan • 26 Aug 2022
1:10
Immune dysregulation in myeloma and impact on disease progression
David Avigan • 26 Aug 2022
3:31
Vaccines and immunotherapy in hematological malignancies
David Avigan • 8 Sep 2020

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals